Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...
If Vertex gets the drug reimbursed in the UK and other countries, it will update the guidance, Arbuckle said. Kalydeco (ivacaftor), Vertex’s oldest drug generated sales of $1.01 billion last ...
The NHS has blinked first and improved the terms of a five-year deal that has been on the table since last year that aims to reimburse all of Vertex’s drugs, including those that have yet to be ...
Dr. Ordonez was previously Chief Medical Officer at two biotech companies and has significant expertise with both early and late-stage drug development. She previously led clinical development ...